You can buy Enhertu at the lowest price in the online pharmacy Nextgen.ooo . Trastuzumab deruxtecan is a modern antitumor agent belonging to the class of antibody–drug conjugates and is used for the treatment of HER2-expressing malignancies. The drug consists of a humanized monoclonal antibody targeting the HER2 receptor linked to a potent topoisomerase I inhibitor. This design enables selective delivery of the cytotoxic payload directly to HER2-expressing tumor cells, thereby enhancing antitumor efficacy while reducing systemic toxicity.
 
A key distinguishing feature of trastuzumab deruxtecan is the presence of a cleavable peptide linker that connects the antibody with the cytotoxic drug. After the antibody binds to the HER2 receptor and the complex is internalized into the tumor cell, the linker is enzymatically cleaved, releasing the active cytotoxic agent inside the cell. This mechanism contributes to the strong antitumor activity of the drug and enables a bystander effect, allowing the released payload to affect neighboring tumor cells with lower levels of HER2 expression. Trastuzumab deruxtecan was developed by Daiichi Sankyo in collaboration with AstraZeneca and received its first approval from the FDA in 2019.
 
Trastuzumab deruxtecan is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer (IHC 3+ or ISH positive) who have previously received an anti-HER2–based regimen. The drug may be used in patients with metastatic disease or in those whose cancer recurred during or within six months after completion of neoadjuvant or adjuvant therapy. In clinical practice, trastuzumab deruxtecan is also used in patients previously treated with trastuzumab emtansine (T-DM1). In addition, the drug may be administered in combination with pertuzumab as a first-line therapy for adult patients with unresectable or metastatic HER2-positive breast cancer.
 
Beyond tumors with high HER2 expression, trastuzumab deruxtecan has demonstrated significant clinical activity in HER2-low breast cancer (IHC 1+ or IHC 2+/ISH−). It is indicated for patients with unresectable or metastatic disease who have previously received chemotherapy in the metastatic setting or who developed disease recurrence during or within six months after completing adjuvant chemotherapy. Furthermore, trastuzumab deruxtecan is indicated for hormone receptor (HR)-positive HER2-low or HER2-ultralow breast cancer (IHC 0 with membrane staining) that has progressed following one or more endocrine therapies in the metastatic setting.